The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Infliximab Biosimilar Receives FDA Approval

Infliximab Biosimilar Receives FDA Approval

April 6, 2016 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

dreamstime_m_7194888croppedApril 5, 2016, marks a revolutionary day in the treatment of autoimmune diseases: The U.S. Food and Drug Administration (FDA) has approved an infliximab (Remicade) biosimilar, known as Inflectra (infliximab-dyyb). Infliximab-dyyb, which is administered by intravenous infusion, is the first biosimilar drug approved to treat rheumatic disease in the U.S.1

You Might Also Like
  • Novartis Receives EU Approval for Infliximab Biosimilar Zessly
  • Adalimumab-atto, Biosimilar to Humira, Receives FDA Approval
  • Rheumatology Drug Updates: Infliximab Biosimilar Gets FDA Approval & More
Also By This Author
  • FDA Updates Boxed Warning of Benzodiazepines, Adding Risks for Abuse & Addiction

With the exception of pediatric ulcerative colitis, infliximab-dyyb has received approval with all of the indications of the reference product, including for:

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE
  • Adult patients and pediatric patients (ages six years and older) with moderate to severe active Crohn’s disease who have had an inadequate response to conventional therapy;
  • Adult patients with moderate to severe active ulcerative colitis who have had an inadequate response to conventional therapy;
  • Patients with moderate to severe active rheumatoid arthritis in combination with methotrexate;
  • Patients with active ankylosing spondylitis;
  • Patients with active psoriatic arthritis; and
  • Adult patients with chronic severe plaque psoriasis.

(Note: Infliximab-dyyb was approved for adult indications of its reference biological. It is not yet FDA approved for pediatric ulcerative colitis.)

Prescribing information is already available on the FDA website at Drugs @ FDA and in the Purple Book.2

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In a statement released April 6, the ACR welcomed the introduction of biosimilars to the U.S. healthcare system. It is “hopeful that the decrease in cost resulting from the availability of safe and effective biosimilars in the U.S. will increase our patients’ access to life-changing therapies and improve their overall health.

“While America’s rheumatologists support the development of new biosimilar therapies, the safety of our patients remains our highest priority. As such, we encourage the FDA to continue to apply distinct names for future biosimilars, and to maximize clarity in the labeling of biosimilars, specifically with respect to their interchangeable status and the origins (reference drug versus biosimilar) of clinical data upon which FDA approval is based.”


Michele B. Kaufman, PharmD, CGP, RPh, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

References

  1. U.S. Food and Drug Administration. News release: FDA approves Inflectra, a biosimilar to Remicade. 2016 Apr 5.
  2. U.S. Food and Drug Administration. Purple book: Lists of licensed biological products with reference product exclusivity and biosimilarity or interchangeability evaluations. 2016 Apr.

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: FDA, Food and Drug Administration, infliximab, infliximab-dyyb

You Might Also Like:
  • Novartis Receives EU Approval for Infliximab Biosimilar Zessly
  • Adalimumab-atto, Biosimilar to Humira, Receives FDA Approval
  • Rheumatology Drug Updates: Infliximab Biosimilar Gets FDA Approval & More
  • FDA Releases Biosimilar Guidance, Medicare Will Cover Infliximab-dyyb & More

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Patient & Caregiver Resources

Find a rheumatology provider. Learn about your condition and how to live with it. English and Spanish language resources.

View Patient & Caregiver Resources »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)